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Abstract
Anthracimycin is a recently discovered novel marine-derived compound with activity against 
Bacillus anthracis. We tested anthracimycin against an expanded panel of Staphylococcus aureus 
strains in vitro and in vivo. All strains of S. aureus tested, including methicillin-sensitive (MSSA), 
methicillin-resistant (MRSA), and vancomycin-resistant strains of S. aureus were sensitive to 
anthracimycin at minimum inhibitory concentrations (MIC) of < 0.25 mg/L. Although its post-
antibiotic effects were minimal, anthracimycin exhibited potent and rapid bactericidal activity, 
with a > 4-log kill of USA300 MRSA within 3 hours at 5 times its MIC. At concentrations 
significantly below the MIC, anthracimycin slowed MRSA growth and potentiated the bactericidal 
activity of the human cathelicidin, LL-37. The bactericidal activity of anthracimycin was 
somewhat mitigated in the presence of 20% human serum, and the compound was minimally toxic 
to human cells, with an IC50 = 70 mg/L against human carcinoma cells. At concentrations near the 
MIC anthracimycin inhibited S. aureus nucleic acid synthesis as determined by optimized 
macromolecular synthesis methodology, with inhibition of DNA and RNA synthesis occurring in 
the absence of DNA intercalation. Anthracimycin at a single dose of 1 or 10 mg/kg was able to 
protect mice from MRSA-induced mortality in a murine peritonitis model of infection. 
Anthracimycin provides an interesting new scaffold for future development of a novel MRSA 
antibiotic.
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The continued prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections 
represents a major clinical challenge in the US.1,2 Complicating this fact, the rate of new 
antibiotic discovery over the last decade has not nearly kept pace with the rapid 
development of antibiotic resistance.3 Discovery of novel chemical entities with potent 
antibiotic activities is critical to continue the pipeline of therapeutic development. Marine-
derived bacteria represent an important source of new chemical scaffolds with anti-MRSA 
activity.4-8 A novel tricyclic dione, termed anthracimycin, was recently purified from a 
previously uncharacterized marine-derived species of Streptomycetes and found to have 
potent activity against Bacillus anthracis and other Gram-positive bacteria.9 However, its 
activity against clinically-relevant drug-resistant pathogens including MRSA is unknown. 




Anthracimycin was purified exactly as described from the marine-derived Streptomyces 
strain CNH365,9 and the structure of the purified compound was determined by combined 
spectroscopic methods and confirmed by a single crystal X-ray experiment (Figure 1).9
Minimum Inhibitory Concentration (MIC) Assays
Antimicrobial activity was evaluated by broth microdilution according to CLSI guidelines 
(Clinical and Laboratory Standards Institute. 2009. M100-S19 Methods for dilution 
antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th 
ed. CLSI, Wayne, PA). MIC analysis in serum was done as previously described10 by 
addition of 20% pooled human serum (collected from > 5 donors according to an approved 
UCSD Institutional Review Board protocol). Bacterial viability at the end of the assay was 
determined by addition of resazurin to the wells. The MIC in serum was then determined to 
be the lowest compound concentration that did not produce a visible conversion of the 
resazurin (blue color) to resorufin (pink color).10
Time-Kill Kinetics
Anthracimycin time-kill kinetics and post-antibiotic effects were performed in duplicate by 
broth macrodilution. For the time-kill kinetics anthracimycin at 0x, 1x, 5x, 10x, or 20x the 
MIC (MIC = 0.125 mg/L for USA300 MRSA strain TCH1516) was added to CA-MHB in 
duplicate sterile polystyrene tubes (Falcon, Bedford MA). The media was then inoculated 
with ~ 5 x 105 colony-forming units (CFU)/mL in a final volume of 5 mL, and the tubes 
were incubated in a 37°C shaking incubator (New Brunswick). Viable bacteria over time 
were quantitated by removal of 25 μL aliquots for serial dilution in phosphate-buffered 
saline and plating on Todd-Hewitt agar (Hardy Diagnostics, Santa Maria, CA). Time-kill 
kinetic studies were performed in triplicate.
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MRSA strain TCH1516 was inoculated into 5 mL of CA-MHB containing anthracimycin 
(MIC = 0.125 mg/L) or vancomycin (MIC = 0.78 mg/L) at 1x or 10x MIC and incubated in 
a shaking incubator at 37°C. At one hour the bacteria were pelleted and then washed twice 
in 10 mL of phosphate-buffered saline and then resuspended in 5 mL CA-MHB. The tubes 
were placed back in the 37°C shaking incubator, and bacterial re-growth was measured at 
selected timepoints up to 24 hours by plating 25 μL samples of serial dilutions on Todd-
Hewitt agar plates and counting colonies.
MRSA Growth in sub-MIC Anthracimycin
Growth curves at sub-MIC concentrations of anthracimycin, vancomycin, or vehicle control 
were performed by broth macrodilution format. Duplicate glass tubes containing CA-MHB 
(5 mL per tube) with either anthracimycin or vancomycin at predetermined concentrations 
were inoculated with ~ 5 x 105 CFU/mL MRSA strain TCH1516 and incubated in a 37°C 
shaking incubator. Growth was monitored at various timepoints up to 24 hours by measuring 
absorbance at 600 nm in a spectrophotometer (Spectronic 20D+, Thermo Scientific, 
Waltham, MA).
Growth studies at sub-MIC anthracimycin and LL-37 were done in broth microdilution 
format in 96 well plates using RPMI supplemented with 5% Luria broth (RPMI/LB). 
RPMI/LB (0.2 mL) containing ½x MIC of either: LL-37 (LL-37 MIC in RPMI/LB = 16 
μM), anthracimycin, LL-37 in combination with anthracimycin, or vehicle was inoculated 
with ~ 5 – 10 × 105 CFU/mL MRSA strain TCH1516. The plates were incubated at 37°C, 
and bacterial survival over time was monitored by plating 25 μL serial dilutions on Todd-
Hewitt agar for quantitative cultures.
Mammalian Cell Cytotoxicity
We assessed mammalian cytotoxicity using the human cervical carcinoma line HeLa (ATCC 
CCL-2). HeLa cells were plated at a density of 2 × 104 cells per well of sterile flat-bottom 
96 well tissue-culture-treated plates (Corning), and anthracimycin was added at increasing 
concentrations. The plates were incubated in 5% CO2, 37°C, and cell viability 
(proliferation) was analyzed at 72 hours using the Promega Cell Proliferation kit (Promega, 
Madison, WI) according to manufacturer’s instructions, and IC50 was determined.
Mechanism of Action Studies
Anthracimycin mechanism of action studies were carried out using an optimized 
macromolecular synthesis assay11. Briefly, S. aureus strain ATCC 29213 was grown to mid-
logarithmic phase in CA-MHB. Macromolecular synthesis in the presence of increasing 
doses of anthracimycin was monitored by measuring the incorporation of radiolabeled 
precursors of DNA, RNA, protein and cell wall synthesis ([3H]-Thymidine, [3H]-Uridine, 
[3H]-Leucine, and [3H]-N-Acetylglucosamine, respectively) in the presence of increasing 
anthracimycin. The extent by which synthesis of each pathway was inhibited was 
determined by calculating the difference in label incorporation relative to untreated controls. 
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DNA intercalation was examined using a commercially available kit (Topogen) and 
observation of the products by agarose gel electrophoresis.
Murine Infection Studies
For the in vivo infection studies, eight week old female CD1 mice (Charles River 
Laboratories, Wilmington, MA) were inoculated intraperitoneally with ~ 1 × 109 CFU of 
MRSA strain Sanger 252 (a sequenced hospital-associated MRSA strain) and then treated 
one hour later with a single intraperitoneal dose of anthracimycin (1 or 10 mg/kg) or 
equivalent vehicle control (n = 10 mice per group). Survival was monitored over seven days, 
and mice that appeared moribund were humanely euthanized. This in vivo infection study 
was performed in duplicate, and data from one representative experiment are shown. All 
studies involving animals were reviewed and approved by the University of California San 
Diego Animal Care and Use Committee.
RESULTS
We found that anthracimycin was potent against all strains of S. aureus tested, including 
methicillin-susceptible and –resistant strains and vancomycin-resistant S. aureus, with MIC 
< 0.25 mg/L (Table 1). Anthracimycin was also active against clinical isolates of 
vancomycin-resistant Enterococcus faecalis. The potent Gram-positive activity was, 
however, mitigated in the presence of 20% human serum, which resulted in significant 
increases in the MIC against MRSA and methicillin-sensitive S. aureus (Table 1). Although 
this compound was active against the Gram-negative pathogen, Moraxella catarrhalis (MIC 
= 4 mg/L), other clinically-significant Gram-negatives including Klebsiella pneumoniae and 
Acinetobacter baumannii lacked anthracimycin susceptibility, with MIC >64 mg/L for these 
strains.
Anthracimycin exhibited rapid killing kinetics, with a > 4-log kill of USA300 MRSA within 
3 hours at > 5x MIC (Figure 2a). Despite these rapid killing kinetics, anthracimycin showed 
minimal post-antibiotic effects against USA300 MRSA, with re-growth occurring rapidly 
after removal of the compound (Figure 2b). Mammalian cell cytotoxicity over 72 hours 
yielded an IC50 = 70 mg/L, which is several-fold higher than the serum MIC of 16 mg/L for 
USA300 MRSA. Given the rapid killing kinetics, we investigated the effects of sub-
inhibitory concentrations of anthracimycin on USA300 MRSA. Even at 1/16x MIC 
(0.0078mg/L), anthracimycin substantially reduced the growth rate of MRSA during the first 
8 hours of its logarithmic growth phase (Figure 3a). Comparatively, the cell wall antibiotic 
vancomycin had no effect on MRSA growth at 1/2x MIC (0.78 mg/L, Figure 3a). Although 
no interactions with other commonly prescribed MRSA antibiotics including vancomycin 
and daptomycin were detected in traditional checkerboard assays, we tested anthracimycin 
for interactions with a key constituent of the host immune defense, cathelicidin antimicrobial 
peptides. For these studies MRSA was co-incubated with sub-MIC concentrations of both 
anthracimycin and the human cathelicidin LL-37, and bacterial survival was monitored at 
selected time points by plating on agar. The addition of 1/4x MIC anthracimycin reduced 
viable MRSA counts in the presence of 1/2x MIC of LL-37 compared to either 
anthracimycin or LL-37 alone (Figure 3b). Additional studies indicated that this potentiation 
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of activity was significantly mitigated in the presence of 20% human serum (data not 
shown).
Given the potent in vitro activity of anthracimycin, we investigated its mechanism of action 
in S. aureus using an optimized macromolecular synthesis assay to quantitate incorporation 
of radiolabeled precursors11. The primary effect on metabolic labeling was on [3H]-
Thymidine and [3H]-Uridine incorporation, indicating the disruption of DNA and RNA 
synthesis, respectively (Figure 4). Disruption of these pathways occurs around the MIC 
concentration, suggesting that this effect is likely related to the antibacterial mechanism of 
action. Additional secondary effects on protein synthesis were also observed at much higher 
concentrations, at least 10-fold higher than the MIC. Primary disruption of DNA and RNA 
synthesis in metabolic labeling is often associated with DNA intercalators. However, when 
anthracimycin was examined for evidence of DNA intercalation over the same concentration 
range as used in metabolic labeling, no effect on DNA migration was observed relative to 
the untreated control (relaxed plasmid). Concentrations of 128 mg/L, 1000-fold higher than 
the MIC, show no evidence of DNA intercalation (Figure 4). These data suggest that the 
disruption of DNA and RNA synthesis by anthracimycin is not due to DNA intercalation.
To ascertain potential in vivo efficacy of anthracimycin, we tested its ability to protect mice 
from MRSA-induced mortality in a peritonitis model. Female CD1 mice were first infected 
intraperitoneally with ~109 CFU of MRSA strain Sanger 252, a route and inoculum 
producing rapid bacteremia and subsequent lethality. One hour after infection, the mice were 
divided into three groups (n = 10 per group) and received a single intraperitoneal injection of 
either anthracimycin (1 or 10 mg/kg) or equivalent vehicle control; anthracimycin at these 
doses appeared to be well-tolerated by the mice. Anthracimycin at either dose injected post-
infection was sufficient to provide significant protection against mortality over seven days 
compared to infected mice treated with vehicle control alone (Figure 5). These results 
suggest that anthracimycin retained anti-MRSA activity and was also well-tolerated when 
introduced in vivo.
DISCUSSION
The dearth of new chemical entities targeting problematic pathogens such as S. aureus has 
created a vacuum in the availability of novel antibiotics to treat these multidrug-resistant 
pathogens, and new antibiotics are urgently needed. The marine environment has been 
probed for decades as a source of novel scaffolds targeting cancer; however, similar studies 
targeting infectious diseases are much less common. The purification of anthracimycin from 
a marine-derived species of Streptomycetes and initial identification of its Gram-positive 
activity prompted us to explore further the potential of this scaffold as an anti-MRSA 
compound. Our results show that anthracimycin activity extends across 14 strains of S. 
aureus tested, including USA300 strains of MRSA, vancomycin-resistant S. aureus, and 
methicillin-sensitive S. aureus. No significant Gram-negative activity was observed. Human 
serum significantly mitigated but did not completely eliminate anthracimycin activity. 
Despite this serum-induced loss of activity, a single dose of anthracimycin was still 
protective in the murine peritonitis model even when the compound was administered post-
infection. Given this initial demonstration of in vivo activity, investigation of additional 
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dosing regimens for this compound and infection models (cutaneous, pulmonary, systemic) 
is now ongoing.
Anthracimycin demonstrated rapid killing kinetics against MRSA, although the post-
antibiotic effect was quite negligible. It is possible that very little of the compound remains 
associated with the bacteria once it is removed from the media or that anthracimycin is 
highly susceptible to degradation, and future studies will address anthracimycin stability. 
Interestingly, our in vitro data suggest that anthracimycin was still able to exert effects on 
MRSA at concentrations below its MIC. We found a marked increase in lag phase when 
anthracimycin was present at 1/16x MIC; no similar effects were observed with the cell wall 
agent vancomycin up to 1/2x its MIC against MRSA. Notably, sub-MIC anthracimycin was 
able to potentiate the effects of the human cathelicidin LL-37 on MRSA growth. In these 
assays MRSA was able to grow during 24 hours in the presence of 1/2x MIC LL-37 or 1/4x 
MIC anthracimycin; however, no growth over the same time period was observed when the 
two were combined at those respective concentrations. It is possible that anthracimycin may 
act in synergy with LL-37 to hinder MRSA growth. This sensitization is not without 
precedent; for example, at well below its MIC, ampicillin has previously been shown to 
sensitize ampicillin-resistant Enterococcus to LL-37-mediated killing.12 Additional studies 
will continue to investigate anthracimycin interactions with the host immune system, 
including with other host-derived antimicrobial peptides.
In summary, our initial in vitro and in vivo studies suggest that the anthracimycin scaffold 
may serve as a viable lead for a medicinal chemistry effort to achieve a useful new MRSA 
therapeutic.
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Figure 1. Chemical structure of anthracimycin
A single crystal X-ray experiment was used to confirm the structure of anthracimycin as 
determined by combined spectroscopic methods.
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Figure 2. Kinetics of anthracimycin activity against USA300 MRSA (strain TCH1516)
(a) Time-kill kinetics of anthracimycin at 1x, 5x, 10x, or 20x its MIC (MIC = 0.125 mg/L) 
during 24 hour incubation. (Note that the data points for the 5x, 10x, and 20x MIC 
anthracimycin are superimposed on the graph.) (b) Post-antibiotic effect of anthracimycin 
against USA300 MRSA (strain TCH1516) compared to vancomycin. The post-antibiotic 
effect was measured by incubating MRSA with anthracimycin or vancomycin for one hour 
(vertical line at 0 hr on the graph) and assessing 24 hour regrowth (viable bacteria) after 
washing the bacteria to remove the antibiotics. (Note that the data points for the 1x and 10x 
MIC vancomycin are nearly superimposed on the graph.)
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Figure 3. Effects of sub-minimal inhibitory concentrations of anthracimycin on USA300 MRSA 
growth and antimicrobial peptide sensitivity
(a) Growth curves of MRSA (strain TCH1516) in the presence of vehicle or increasing sub-
minimal inhibitory concentrations of anthracimycin (MIC = 0.125 mg/L) compared to 1/2x 
or 1x MIC vancomycin (vancomycin MIC = 0.78 mg/L). Turbidity as a measure of bacterial 
growth was monitored by optical density (A600) over time in duplicate tubes. (b) Killing of 
MRSA strain TCH1516 during incubation with: vehicle (MRSA alone), 1/2x MIC LL-37 
alone, 1/4x anthracimycin alone, or 1/2x MIC LL-37 + 1/4x MIC anthracimycin. Surviving 
bacteria were enumerated by plating on agar, and the data represent mean +/- SD of 
duplicate samples.
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Figure 4. Macromolecular synthesis in the presence of increasing anthracimycin
Incorporation of radiolabeled precursors of DNA, RNA, protein and cell wall synthesis 
([3H]-Thymidine, [3H]-Uridine, [3H]-Leucine, and [3H]-N-Acetylglucosamine, respectively) 
was measured using S. aureus ATCC29213 (MSSA). DNA intercalation was examined 
using a commercially available kit. In the absence of DNA intercalation, relaxed plasmid 
migrates as a series of discrete topomers, with a characteristic ladder pattern. In contrast, 
intercalation results in a change in linking number, resulting in a change in the migration 
pattern. “SC” = supercoiled; “Rel” = relaxed.
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Figure 5. Anthracimycin protection of mice from MRSA mortality
Female CD1 mice were infected intraperitoneally (~ 109 colony-forming units per mouse) 
with MRSA strain Sanger 252 and treated intraperitoneally one hour postinfection with 
either anthracimycin (1 or 10 mg/kg) or vehicle control (n = 10 mice per group). Survival 
was monitored over 7 days. These survival data are from one representative study that was 
repeated a total of two times.
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Table 1
Minimum Inhibitory Concentration (MIC) Values
Strain MIC (mg/L)
MRSA
Sanger 252 (USA200) 0.063









UAMS1 0.125 (8 in 20% serum)
NRS77 (sequenced ST8) 0.16
NRS135 (ST8) 0.16
RN4220 0.125 (32 in 20% serum)
Newman 0.16
Non-S. aureus
Enterococcus faecalis (ATCC 51299) 0.25
E. faecalis isolate 6981 0.125
B. anthracis (Sterne) 0.03
Moraxella catarrhalis (ATCC 25238) 4
Pseudomonas aeruginosa (ATCC 27853) > 64
Klebsiella pneumoniae (ATCC 700603) > 64
Acinetobacter baumannii (ATCC 17978) > 64
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